Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00847613
Registration number
NCT00847613
Ethics application status
Date submitted
17/02/2009
Date registered
19/02/2009
Date last updated
16/05/2024
Titles & IDs
Public title
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Query!
Scientific title
Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Query!
Secondary ID [1]
0
0
A3921044
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550
Treatment: Drugs - Placebo
Treatment: Drugs - CP-690,550
Treatment: Drugs - Placebo
Treatment: Drugs - CP-690,550
Experimental: Sequence 1 -
Experimental: Sequence 2 -
Placebo Comparator: Sequence 3 -
Placebo Comparator: Sequence 4 -
Treatment: Drugs: CP-690,550
Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Treatment: Drugs: CP-690,550
Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
Treatment: Drugs: CP-690,550
Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Treatment: Drugs: CP-690,550
Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Treatment: Drugs: Placebo
Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Treatment: Drugs: CP-690,550
Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
Treatment: Drugs: Placebo
Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Treatment: Drugs: CP-690,550
Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6
Query!
Assessment method [1]
0
0
ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.
Query!
Timepoint [1]
0
0
Month 6
Query!
Primary outcome [2]
0
0
Changes From Baseline in Modified Total Sharp Score (mTSS) at Month 6
Query!
Assessment method [2]
0
0
mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.
Query!
Timepoint [2]
0
0
Baseline, Month 6
Query!
Primary outcome [3]
0
0
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3
Query!
Assessment method [3]
0
0
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities over past week. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty;2=much difficulty; 3=unable to do. Overall score was computed as sum of domain sc ores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.
Query!
Timepoint [3]
0
0
Baseline, Month 3
Query!
Primary outcome [4]
0
0
Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6
Query!
Assessment method [4]
0
0
DAS28-4 (ESR) calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (=<) 3.2 implied low disease activity, greater than (>) 3.2 to 5.1 implied moderate to high disease activity and less than (<) 2.6=remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.
Query!
Timepoint [4]
0
0
Month 6
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 1 and 3
Query!
Assessment method [1]
0
0
ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Query!
Timepoint [1]
0
0
Month 1, 3
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [2]
0
0
ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Query!
Timepoint [2]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 1, 3 and 6
Query!
Assessment method [3]
0
0
ACR50 response: greater than or equal to >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Query!
Timepoint [3]
0
0
Month 1, 3, 6
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [4]
0
0
ACR50 response: greater than or equal to >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Query!
Timepoint [4]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 1, 3 and 6
Query!
Assessment method [5]
0
0
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Query!
Timepoint [5]
0
0
Month 1, 3, 6
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [6]
0
0
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Query!
Timepoint [6]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [7]
0
0
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6
Query!
Assessment method [7]
0
0
DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Query!
Timepoint [7]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [8]
0
0
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [8]
0
0
DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 indicated low disease activity, >3.2 to 5.1 indicated moderate to high disease activity and <2.6 = remission.
Query!
Timepoint [8]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [9]
0
0
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6
Query!
Assessment method [9]
0
0
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Query!
Timepoint [9]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [10]
0
0
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [10]
0
0
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Query!
Timepoint [10]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [11]
0
0
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])
Query!
Assessment method [11]
0
0
DAS28-4 (CRP) was calculated from SJC and TJC using the 28 joints count, CRP [mg/L] and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 [CRP] <=3.2 implied low disease activity, DAS28-4 [CRP] >3.2 to 5.1 implied moderate to high disease activity and DAS28 <2.6 implied remission.
Query!
Timepoint [11]
0
0
Baseline, Month 1, 3, 6, 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [12]
0
0
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])
Query!
Assessment method [12]
0
0
DAS28-3 (ESR) was calculated from the number of SJC and TJC using the 28 joints count and ESR (mm/hr). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Query!
Timepoint [12]
0
0
Baseline, Month 1, 3, 6, 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [13]
0
0
Modified Total Sharp Scores (mTSS) at Baseline
Query!
Assessment method [13]
0
0
mTSS = sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Query!
Timepoint [13]
0
0
Baseline
Query!
Secondary outcome [14]
0
0
Modified Total Sharp Scores (mTSS) at Month 12 and 24
Query!
Assessment method [14]
0
0
mTSS = sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Query!
Timepoint [14]
0
0
Month 12, 24
Query!
Secondary outcome [15]
0
0
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Month 1, 3 and 6
Query!
Assessment method [15]
0
0
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.
Query!
Timepoint [15]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [16]
0
0
Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [16]
0
0
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.
Query!
Timepoint [16]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [17]
0
0
Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6
Query!
Assessment method [17]
0
0
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Query!
Timepoint [17]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [18]
0
0
Patient Assessment of Arthritis Pain at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [18]
0
0
Participants rated the severity of arthritis pain on a 0 to 100 mm visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Query!
Timepoint [18]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [19]
0
0
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3, and 6
Query!
Assessment method [19]
0
0
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.
Query!
Timepoint [19]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [20]
0
0
Patient Global Assessment (PtGA) of Arthritis Pain at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [20]
0
0
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.
Query!
Timepoint [20]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [21]
0
0
Physician Global Assessment (PGA) of Arthritis at Baseline, Month 1, 3 and 6
Query!
Assessment method [21]
0
0
Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Query!
Timepoint [21]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [22]
0
0
Physician Global Assessment (PGA) of Arthritis at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [22]
0
0
Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Query!
Timepoint [22]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [23]
0
0
36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6
Query!
Assessment method [23]
0
0
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Query!
Timepoint [23]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [24]
0
0
36-Item Short-Form Health Survey (SF-36) at Month 9, 12, 15, 18, 21 and 24
Query!
Assessment method [24]
0
0
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Query!
Timepoint [24]
0
0
Month 9, 12, 15, 18, 21, 24
Query!
Secondary outcome [25]
0
0
Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6
Query!
Assessment method [25]
0
0
Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.
Query!
Timepoint [25]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [26]
0
0
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6
Query!
Assessment method [26]
0
0
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.
Query!
Timepoint [26]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [27]
0
0
Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12, 18 and 24
Query!
Assessment method [27]
0
0
Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.
Query!
Timepoint [27]
0
0
Month 12, 18, 24
Query!
Secondary outcome [28]
0
0
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12, 18 and 24
Query!
Assessment method [28]
0
0
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.
Query!
Timepoint [28]
0
0
Month 12, 18, 24
Query!
Secondary outcome [29]
0
0
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline, Month 1, 3, and 6
Query!
Assessment method [29]
0
0
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Query!
Timepoint [29]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [30]
0
0
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 12, 18 and 24
Query!
Assessment method [30]
0
0
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Query!
Timepoint [30]
0
0
Month 12, 18, 24
Query!
Secondary outcome [31]
0
0
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline, Month 3 and 6
Query!
Assessment method [31]
0
0
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Query!
Timepoint [31]
0
0
Baseline, Month 3, 6
Query!
Secondary outcome [32]
0
0
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 12, 18 and 24
Query!
Assessment method [32]
0
0
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Query!
Timepoint [32]
0
0
Month 12, 18, 24
Query!
Secondary outcome [33]
0
0
Work Limitations Questionnaire (WLQ) Score at Baseline, Month 3 and 6
Query!
Assessment method [33]
0
0
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).
Query!
Timepoint [33]
0
0
Baseline, Month 3, 6
Query!
Secondary outcome [34]
0
0
Work Limitations Questionnaire (WLQ) Score at Month 12, 18 and 24
Query!
Assessment method [34]
0
0
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).
Query!
Timepoint [34]
0
0
Month 12, 18, 24
Query!
Secondary outcome [35]
0
0
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6
Query!
Assessment method [35]
0
0
Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, emergency room(ER) treatment, diagnostic tests, over-night stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family, friends or housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.
Query!
Timepoint [35]
0
0
Baseline, Month 3, 6
Query!
Secondary outcome [36]
0
0
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12, 18 and 24
Query!
Assessment method [36]
0
0
Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.
Query!
Timepoint [36]
0
0
Month 12, 18, 24
Query!
Secondary outcome [37]
0
0
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Query!
Assessment method [37]
0
0
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.
Query!
Timepoint [37]
0
0
Baseline, Month 3, 6
Query!
Secondary outcome [38]
0
0
Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12, 18 and 24
Query!
Assessment method [38]
0
0
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.
Query!
Timepoint [38]
0
0
Month 12, 18, 24
Query!
Secondary outcome [39]
0
0
Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Query!
Assessment method [39]
0
0
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Query!
Timepoint [39]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [40]
0
0
Number of Days as Assessed Using RA-HCRU at Month 12, 18 and 24
Query!
Assessment method [40]
0
0
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Query!
Timepoint [40]
0
0
Month 12, 18, 24
Query!
Secondary outcome [41]
0
0
Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6
Query!
Assessment method [41]
0
0
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.
Query!
Timepoint [41]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [42]
0
0
Number of Hours Per Day as Assessed RA-HCRU at Month 12, 18 and 24
Query!
Assessment method [42]
0
0
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.
Query!
Timepoint [42]
0
0
Month 12, 18, 24
Query!
Secondary outcome [43]
0
0
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Query!
Assessment method [43]
0
0
Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.
Query!
Timepoint [43]
0
0
Baseline, Month 1, 3, 6
Query!
Secondary outcome [44]
0
0
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12, 18 and 24
Query!
Assessment method [44]
0
0
Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.
Query!
Timepoint [44]
0
0
Month 12, 18, 24
Query!
Eligibility
Key inclusion criteria
- Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pregnancy, severe acute or chronic medical conditions, including serious infections or
clinically significant laboratory abnormalities.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
800
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Maroochydore
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Woodville
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Malvern East
Query!
Recruitment postcode(s) [1]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [3]
0
0
3145 - Malvern East
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Tennessee
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
West Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Wisconsin
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
GO
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
PR
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Rio Grande Do Sul
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
RJ
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
RS
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
SP
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Plovdiv
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Sofia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
British Columbia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Newfoundland and Labrador
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Colombia
Query!
State/province [36]
0
0
Antioquia
Query!
Country [37]
0
0
Colombia
Query!
State/province [37]
0
0
Atlantico
Query!
Country [38]
0
0
Colombia
Query!
State/province [38]
0
0
Cundinamarca
Query!
Country [39]
0
0
Colombia
Query!
State/province [39]
0
0
Santander
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Brno - Zidenice
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Brno
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Hostivice
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Pardubice
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Praha 11 - Chodov
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 1
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Praha 2
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Zlin
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Thessaloniki
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
Andhra Pradesh
Query!
Country [50]
0
0
India
Query!
State/province [50]
0
0
Andra Pradesh
Query!
Country [51]
0
0
India
Query!
State/province [51]
0
0
Karnataka
Query!
Country [52]
0
0
India
Query!
State/province [52]
0
0
Maharashtra
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Fukuoka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Hiroshima
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Ibaraki
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Kanagawa
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Kumamoto
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Miyagi
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Nagasaki
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Saga
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Saitama
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Shizuoka
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Tokyo
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Shinjuku-ku, Tokyo
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Daejeon
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Incheon
Query!
Country [67]
0
0
Korea, Republic of
Query!
State/province [67]
0
0
Seoul
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
DF
Query!
Country [69]
0
0
Mexico
Query!
State/province [69]
0
0
Michoacan
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Warszawa
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Wroclaw
Query!
Country [72]
0
0
Taiwan
Query!
State/province [72]
0
0
Kaohsiung
Query!
Country [73]
0
0
Taiwan
Query!
State/province [73]
0
0
Kweishan, Taoyuan County
Query!
Country [74]
0
0
Taiwan
Query!
State/province [74]
0
0
Taichung
Query!
Country [75]
0
0
Taiwan
Query!
State/province [75]
0
0
Tainan
Query!
Country [76]
0
0
Taiwan
Query!
State/province [76]
0
0
Taipei
Query!
Country [77]
0
0
Ukraine
Query!
State/province [77]
0
0
Crimea
Query!
Country [78]
0
0
Ukraine
Query!
State/province [78]
0
0
Kharkiv
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Kyiv
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Lviv
Query!
Country [81]
0
0
Ukraine
Query!
State/province [81]
0
0
Vinnitsa
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to provide safety and efficacy data to support the development of
CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of
methotrexate.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00847613
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00847613
Download to PDF